Abstract
The inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of cell-free DNA and circulating tumor cells has the potential to change clinical practice by exploiting blood rather than tissue as a source of information. Liquid biopsies are already used to monitor disease response and track the emergence of drug resistance. The suitability of blood-based molecular profiles for early detection and monitoring minimal residual disease is being evaluated. In this review, we address open questions in this fast-evolving field of research.
Original language | English |
---|---|
Pages (from-to) | 172-179 |
Number of pages | 8 |
Journal | Cancer Cell |
Volume | 31 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 13 2017 |
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research